TeraRecon receives first-of-kind FDA determination

TeraRecon receives first-of-kind FDA determination
share Share
Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has successfully completed an FDA regulatory review of its Northstar™ AI Results Explorer, for which the technology and the determination are both firsts-of-kind in the medical imaging industry.  Northstar is designed to work alongside the company’s EnvoyAITM interoperability platform which includes FDA-cleared 3rd party content listed on its EnvoyAI Exchange marketplace. The Northstar determination letter reinforces the company’s commitment to regulatory and quality standards along with transparency in the field of medical imaging artificial intelligence.

The Northstar AI Results Explorer provides an engaging physician user experience which can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians an important way to accept, reject, and interact with AI-derived findings. Through the EnvoyAI marketplace, health systems can enter into a single contractual agreement and confidently run algorithms interchangeably, with a single two-hour software installation.

EnvoyAI is the world's first AI marketplace and the only AI interoperability platform. EnvoyAI customers currently have access to over 80 algorithms with 20 holding regulatory clearances in various global territories.

“As the medical AI market continues to mature, global regulatory bodies are growing ever more vigilant and confident in assessing these emerging technologies” noted Patty O'Brien, Vice President Regulatory Affairs at TeraRecon.   “It is gratifying to work in today’s collaborative regulatory environment and to do our part as an industry partner in the process.”

With deep domain expertise involving class II medical imaging software devices, TeraRecon maintains stringent processes, documentation and quality systems across its design, development and business operations.  The FDA has determined that the Northstar AI Results Explorer is exempt from Class II premarket notification requirements and therefore is considered a Class I medical device alongside their existing Class I EnvoyAI platform.

“TeraRecon technologies are always designed keeping their future value in mind” said Jeff Sorenson, TeraRecon CEO.  “We know that our artificial intelligence solutions are only the tip of the transformation iceberg and that workflows will only grow more sophisticated over time. Product requirements will continue to evolve and become deeply clinical and highly specialized, requiring much more than just a marketplace to deliver them. We expect any advanced AI workflow solutions will require the same level of diligence and sophistication as advanced visualization solutions do today, if not more” said TeraRecon CEO, Jeff Sorenson. 

TeraRecon technologies including the EnvoyAI platform, TeraRecon Northstar AI Results Explorer, and its flagship iNtuition™ advanced visualization solution, will be on display at the Society for Imaging Informatics in Medicine (Book a demo at SIIM) in Aurora, Colorado from June 26th – June 28th, 2019. Online demonstrations are available by contacting TeraRecon at [email protected].  

Published on : Thu, 20 Jun 2019



Related Articles
TeraRecon unveils iNtuition AI Data Extractor

New tool enables vast customer base to automatically convert 3D post-processed studies into rich AI training data sets... Read more

Thales joins forces with Micro-X

Micro-X and Thales join forces to anticipate the growing needs of the 3D imaging market.   Micro-X, the global leader in... Read more

Affidea partners with ScreenPoint Medical to increase diagnostic accuracy of screening mammography with the use of AI

Affidea and ScreenPoint Medical announced a strategic partnership to streamline and improve the clinical performance of... Read more

TeraRecon, physicians, medical imaging, Artificial Intelligence, AI, advanced visualization, EnvoyAI, medical AI, Northstar AI Results Explorer, NorthstarTM AI Results Explorer, Northstar, medical imaging artificial intelligence, AI interoperability platform Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has successfully completed an FDA regulatory review of its NorthstarTM AI Results Explorer, for which the technology and the determination are both

No comment


Please login to leave a comment...

Highlighted Products